216 related articles for article (PubMed ID: 25707611)
1. The Effect of Discontinuing Treatment With Blosozumab: Follow-up Results of a Phase 2 Randomized Clinical Trial in Postmenopausal Women With Low Bone Mineral Density.
Recknor CP; Recker RR; Benson CT; Robins DA; Chiang AY; Alam J; Hu L; Matsumoto T; Sowa H; Sloan JH; Konrad RJ; Mitlak BH; Sipos AA
J Bone Miner Res; 2015 Sep; 30(9):1717-25. PubMed ID: 25707611
[TBL] [Abstract][Full Text] [Related]
2. A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density.
Recker RR; Benson CT; Matsumoto T; Bolognese MA; Robins DA; Alam J; Chiang AY; Hu L; Krege JH; Sowa H; Mitlak BH; Myers SL
J Bone Miner Res; 2015 Feb; 30(2):216-24. PubMed ID: 25196993
[TBL] [Abstract][Full Text] [Related]
3. Single- and multiple-dose randomized studies of blosozumab, a monoclonal antibody against sclerostin, in healthy postmenopausal women.
McColm J; Hu L; Womack T; Tang CC; Chiang AY
J Bone Miner Res; 2014 Apr; 29(4):935-43. PubMed ID: 23996473
[TBL] [Abstract][Full Text] [Related]
4. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass.
Bone HG; Bolognese MA; Yuen CK; Kendler DL; Miller PD; Yang YC; Grazette L; San Martin J; Gallagher JC
J Clin Endocrinol Metab; 2011 Apr; 96(4):972-80. PubMed ID: 21289258
[TBL] [Abstract][Full Text] [Related]
5. Romosozumab increases bone mineral density in postmenopausal Japanese women with osteoporosis: A phase 2 study.
Ishibashi H; Crittenden DB; Miyauchi A; Libanati C; Maddox J; Fan M; Chen L; Grauer A
Bone; 2017 Oct; 103():209-215. PubMed ID: 28687496
[TBL] [Abstract][Full Text] [Related]
6. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD.
Lewiecki EM; Miller PD; McClung MR; Cohen SB; Bolognese MA; Liu Y; Wang A; Siddhanti S; Fitzpatrick LA;
J Bone Miner Res; 2007 Dec; 22(12):1832-41. PubMed ID: 17708711
[TBL] [Abstract][Full Text] [Related]
7. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
Li M; Zhang ZL; Liao EY; Chen DC; Liu J; Tao TZ; Wu W; Xia WB; Lu YJ; Sheng ZF; Lu CY; Meng GL; Xu L; Zhang WJ; Hu YY; Xu L
Menopause; 2013 Jan; 20(1):72-8. PubMed ID: 22968256
[TBL] [Abstract][Full Text] [Related]
8. Anti-sclerostin antibodies: utility in treatment of osteoporosis.
Clarke BL
Maturitas; 2014 Jul; 78(3):199-204. PubMed ID: 24842796
[TBL] [Abstract][Full Text] [Related]
9. Blosozumab in the treatment of postmenopausal women with osteoporosis: a systematic review and meta-analysis.
Su Y; Wang W; Liu F; Cai Y; Li N; Li H; Li G; Ma L
Ann Palliat Med; 2022 Oct; 11(10):3203-3212. PubMed ID: 36367007
[TBL] [Abstract][Full Text] [Related]
10. Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect.
Eisman JA; Bone HG; Hosking DJ; McClung MR; Reid IR; Rizzoli R; Resch H; Verbruggen N; Hustad CM; DaSilva C; Petrovic R; Santora AC; Ince BA; Lombardi A
J Bone Miner Res; 2011 Feb; 26(2):242-51. PubMed ID: 20740685
[TBL] [Abstract][Full Text] [Related]
11. Sclerostin and DKK1 in postmenopausal osteoporosis treated with denosumab.
Gatti D; Viapiana O; Fracassi E; Idolazzi L; Dartizio C; Povino MR; Adami S; Rossini M
J Bone Miner Res; 2012 Nov; 27(11):2259-63. PubMed ID: 22692843
[TBL] [Abstract][Full Text] [Related]
12. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
Bone HG; Bolognese MA; Yuen CK; Kendler DL; Wang H; Liu Y; San Martin J
J Clin Endocrinol Metab; 2008 Jun; 93(6):2149-57. PubMed ID: 18381571
[TBL] [Abstract][Full Text] [Related]
13. Odanacatib in the treatment of postmenopausal women with low bone mineral density: five years of continued therapy in a phase 2 study.
Langdahl B; Binkley N; Bone H; Gilchrist N; Resch H; Rodriguez Portales J; Denker A; Lombardi A; Le Bailly De Tilleghem C; Dasilva C; Rosenberg E; Leung A
J Bone Miner Res; 2012 Nov; 27(11):2251-8. PubMed ID: 22777865
[TBL] [Abstract][Full Text] [Related]
14. Multiple doses of sclerostin antibody romosozumab in healthy men and postmenopausal women with low bone mass: a randomized, double-blind, placebo-controlled study.
Padhi D; Allison M; Kivitz AJ; Gutierrez MJ; Stouch B; Wang C; Jang G
J Clin Pharmacol; 2014 Feb; 54(2):168-78. PubMed ID: 24272917
[TBL] [Abstract][Full Text] [Related]
15. The effect of continuous oestradiol with intermittent norgestimate on bone mineral density and bone turnover in post-menopausal women.
Arrenbrecht S; Caubel P; Garnero P; Felsenberg D
Maturitas; 2004 Jul; 48(3):197-207. PubMed ID: 15207885
[TBL] [Abstract][Full Text] [Related]
16. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
McClung M; Recker R; Miller P; Fiske D; Minkoff J; Kriegman A; Zhou W; Adera M; Davis J
Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of teriparatide in increasing bone mineral density in postmenopausal women with osteoporosis--an Indian experience.
Sethi BK; Chadha M; Modi KD; Kumar KM; Mehrotra R; Sriram U
J Assoc Physicians India; 2008 Jun; 56():418-24. PubMed ID: 18822620
[TBL] [Abstract][Full Text] [Related]
18. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial.
Deal C; Omizo M; Schwartz EN; Eriksen EF; Cantor P; Wang J; Glass EV; Myers SL; Krege JH
J Bone Miner Res; 2005 Nov; 20(11):1905-11. PubMed ID: 16234962
[TBL] [Abstract][Full Text] [Related]
19. Effect of nitroglycerin ointment on bone density and strength in postmenopausal women: a randomized trial.
Jamal SA; Hamilton CJ; Eastell R; Cummings SR
JAMA; 2011 Feb; 305(8):800-7. PubMed ID: 21343579
[TBL] [Abstract][Full Text] [Related]
20. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.
Murphy MG; Weiss S; McClung M; Schnitzer T; Cerchio K; Connor J; Krupa D; Gertz BJ;
J Clin Endocrinol Metab; 2001 Mar; 86(3):1116-25. PubMed ID: 11238495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
